Progress in the development of anti-hepatitis C virus nucleoside and nucleotide prodrugs

Future Medicinal Chemistry

Volumn 4, Issue 5, 2012, Pages 625-650

  Madela, Karolina ^a   McGuigan, Christopher ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2' C METHYLADENOSINE PROTIDE; 2' C METHYLGUANOSINE PROTIDE; 2' DEOXY 2' FLUORO 2' METHYLCYTIDINE; 2' METHYLCYTIDINE; 3',5' CYCLIC PHOSPHORAMIDATE; 3',5' CYCLIC PROTIDE; 4' AZIDOCYTIDINE; 4' C AZIDOCYTIDINE; 4' C AZIDOURIDINE; 7 DEAZA 2' C METHYLADENOSINE PROTIDE; ALPHA INTERFERON; ANTIVIRUS AGENT; BALAPIRAVIR; BETA DEXTRO 2' DEOXY 2' FLUORO 2' C METHYLURIDINE PROTIDE; DACLATASVIR; HEPDIRECT PRODRUG; MERICITABINE; NON NUCLEOSIDE INHIBITOR; NUCLEOSIDE ANALOG; NUCLEOSIDE INHIBITOR; NUCLEOTIDE INHIBITOR; PEGINTERFERON; PRADEFOVIR; PRODRUG; PSI 7851; PSI 7977; RIBAVIRIN; S ACYL 2 THIOETHYL PROTIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALOPICITABINE;

ANEMIA; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTHRALGIA; COGNITIVE DEFECT; CYTOPENIA; DEPRESSION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG WITHDRAWAL; ENZYME INHIBITION; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NAUSEA; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; RETINOPATHY; REVIEW; THYROID DISEASE; VIRUS GENOME; VIRUS LOAD; VIRUS REPLICATION; VOMITING;

ANTIVIRAL AGENTS; ENZYME INHIBITORS; HEPACIVIRUS; HEPATITIS C; HUMANS; NUCLEOSIDES; PRODRUGS; RNA REPLICASE; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84859446862     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.10     Document Type: Review

References (131)

1. Schiff ER. Diagnosis and treating hepatitis C virus infection. Am. J. Manag. Care 17(Suppl. 4), S108-S115 (2011).
2. Giovanni M, Joanne ET, Steven SC et al. Characterization of resistance to non-obligate chain-Terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J. Biol. Chem. 278, 49164-49170 (2003).
3. Hepatitis C - global prevalence (update). Wkly Epidemiol. Rec. 75, 18-19 (2000).
4. Liang TJ, Reherman B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Annu. Intern. Med. 132, 296-305 (2000). (Pubitemid 30106261)
5. Thomas DL, Seeff LB. Natural history of hepatitis C. Clin. Liver Dis. 9, 383-398 (2003). (Pubitemid 40968202)
6. Chun IY, Bor-Luen C. A new insight into hepatitis C vaccine development. J. Biomed. Biotech. 548280, 1-12 (2010).
7. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244, 359-362 (1989). (Pubitemid 19117877)
8. Freeman AJ, Marinos G, Ffrench RA, Lloyd AR. Immunopathogenesis of hepatitis C virus infection. Immunol. Cell Biol. 79, 515-536 (2001). (Pubitemid 33070441)
9. Burke KP, Cox AL. A hepatitis C virus evasion of adaptive immune response - A model for viral persistence. Immunol. Res. 47, 216-227 (2010).
10. Neumann AU, Lam NP, Dahari H, Gretch DR, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-a therapy. Science 282, 103-107 (1998). (Pubitemid 28471138)
11. Smith DB, Pathirana S, Davidson F et al. The origin of hepatitis C virus genotypes. J. Gen. Virol. 78, 321-328 (1997). (Pubitemid 27075628)
12. Lee CM, Hung CH, Lu SN, Changchien CS. Hepatitis C virus genotypes: Clinical relevance and therapeutic implications. Chang Gung Med. J. 31, 16-24 (2008).
13. Soriano V, Peters MG, Zeuzem S. New therapies for hepatitis C virus infection. Clin. Infect. Dis. 48, 313-320 (2009).
14. Zeuzem S, Berg T, Moeller B et al. Expert opinion on the treatment of patients with chronic hepatitis C. J. Viral Hepat. 16, 75-90 (2009).
15. Sarasin-Filipowicz M. Interferon therapy of hepatitis C: Molecular insights into success and failure. Swiss Med. Wkly 140, 3-11 (2010).
16. Pearlman BL, Traub N. Sustained virological response to antiviral therapy for chronic hepatitis C virus infection: A cure and so much more. Clin. Infect. Dis. 52, 889-900 (2011).
17. Fried MW, Shiffman ML, Reddy KR et al. PEGinterferon alfa-2a plus ribavirin for chronic hepatitis C infection. N. Engl. J. Med. 347, 975-982 (2002).
18. Aspinall RJ, Pockros PJ. The management of side effects during therapy for hepatitis C. APT 20, 917-929 (2004). (Pubitemid 39593272)
19. Aurora R, Donlin MJ, Cannon NA, Travis JE. Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans. J. Clin. Invest. 119, 225-236 (2009).
20. Asselah T, Benhamou Y, Marcellin P. Protease and polymerase inhibitors for the treatment of hepatitis C. Liver Intl 29, 57-67 (2009).
21. Simmonds P. Genetic diversity and evaluation of hepatitis C virus - 15 years on. J Gen. Virol. 85, 3173-3188 (2004). (Pubitemid 39445434)
22. Ago H, Adachi T, Yoshida A et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Cell 11, 1417-1426 (1999). (Pubitemid 29529882)
23. Lesburg CA, Cable MB, Ferrari E et al. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encirculated active site. Nat. Struct. Biol. 6, 937-943 (1999). (Pubitemid 29463307)
24. Ranjith-Kumar CT, Gutshall L, Sarisky RT, Kao CC. Multiple interactions within the hepatitis C virus RNA polymerase represses primer-dependentt RNA synthesis. J. Mol. Biol. 330, 675-685 (2003).
25. Harrus D, El-Sayed NA, Simister PC et al. Further insights into the roles of GTP and C-Terminus of hepatitis C virus polymerase in the initiation of RNA synthesis. J. Biol. Chem. 285, 32906-32918 (2010).
26. Furman PA, Lam AM, Murakami E. Nucleoside analogue inhibitors of hepatitis C viral replication: Recent advances, challenges and trends. Future Med. Chem. 1, 1429-1452 (2009).
27. Betzi S, Eydoux C, Bussetta C et al. Identification of allosteric inhibitors blocking the hepatitis C virus polymerase NS5B in the RNA synthesis initiation step. Antiviral Res. 84, 48-59 (2009).
28. Tomei L, Altamura S, Bartholomew L et al. Characterization of inhibition of hepatitis C virus RNA replication by nonnucleosides. J. Virol. 78, 938-946 (2004). (Pubitemid 38067615)
29. Summa V, Petrocchi A, Pace P et al. Discovery of alpha, gamma-diketo acids as potent selective and reversible inhibitors of hepatitis C virus NS5b RNA-dependent RNA polymerase. J. Med. Chem. 47, 14-17 (2004). (Pubitemid 38040485)
30. He Y, Duan W, Tan SL. Emerging host cell targets for hepatitis C therapy. Drug Discov. Today 12, 209-217 (2007).
31. Tomei A, Altamura S, Paonessa G, De Francesco R, Migliaccio G. HCV antiviral resistance: The impact of in vitro studies on the development of antiviral agents targeting the viral NS5B polymerase. Antivir. Chem. Chemother. 16, 225-245 (2005). (Pubitemid 41139709)
32. Shim J, Larson G, Lai V, Naim S, Wu JZ. Canonical 3′- deoxyribonucleotides as a chain terminator for HCV NS5B RNA-dependent RNA polymerase. Antivir. Res. 58, 243-251 (2003). (Pubitemid 36589015)
33. Gallois-Montbrun S, Chen Y, Dutartre H et al. Structural analysis of the activation of ribavirin analogs by NDP kinase: Comparison with other ribavirin targets. Mol. Pharmacol. 63, 538-546 (2003). (Pubitemid 36297323)
34. De Clercq E. The design of drugs for HIV and HCV. Nat. Rev. Drug Discov. 6, 1001-1018 (2006). (Pubitemid 350213865)
35. Sofia MJ. Nucleotide prodrugs for HCV therapy. Antivir. Chem. Chemother. 22, 23-49 (2011).
36. Bobeck DR, Schinazi RF, Coats SJ. Advances in nucleoside monophosphate prodrugs as anti-HCV agents. Antivir. Ther. 15, 935-950 (2010).
37. Brown NA. Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors. Part I: Nucleoside analogues. Expert Opin. Investig. Drugs 18, 709-725 (2009).
38. Carroll SS, Olsen DB. Nucleoside analog inhibitors of hepatitis C viral replication. Infect. Disord. Drug Target. 6, 17-29 (2009). (Pubitemid 43796633)
39. Pierra C, Amador A, Benzaria S et al. Synthesis and pharmacokinetics of Valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2′-C-Methylcytidine. J. Med. Chem. 49, 6614-6620 (2006). (Pubitemid 44657456)
40. Le Pogam S, Jiang WR, Leveque V et al. In vitro selected Con1 subgenomic replicons resistant to 2′-C-methyl-cytidine or to R1479 show lack of cross resistance. Virology 351, 349-359 (2006). (Pubitemid 44108072)
41. Ali S, Leveque V, LePogam S et al. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitors PSI6130 lack cross-resistance with R1479. Antimicrob. Agents Chemother. 52, 4356-4369 (2008).
42. Bichko V. Lallos L. Soubasakos M et al. Valopicitabine (NM 283) is fully active against known HCV protease resistance mutations in vitro. J. Hepat. 46(Suppl. 1), S163 (2007).
43. Sherman KE, Lawitz E, O'Brien CB, Godofsky E, Brown NA. Valopicitabine (NM283) plus PEG-interferon for chronic hepatitis C in treatment naïve and nonresponders patients: Interim Phase IIb results. J. Clin. Virol. 36(Suppl. 2), S24 (2006).
44. Kwong AD, McNair L, Jacobson I, George S. Recent progress in the development of selective hepatitis C virus NS3. ast;4A protease and NS5B polymerase inhibitors. Curr. Opin. Pharmacol. 8, 522-531 (2008).
45. Smith DB, Martin JA, Klumpp K et al. Design, synthesis, and antiviral properties of 4'-substituted ribonucleosides as inhibitors of hepatitis C virus replication: The discovery of R1479. Bioorg. Med. Chem. Lett. 17, 2570-2576 (2007). (Pubitemid 46509839)
46. Roberts SK, Cooksley G, Dore GJ et al. Robust antiviral activity of R1626, a novel nucleoside analog: A randomized, placebo-controlled study in patients with chronic hepatitis C. Hepatology 48, 398-406 (2008).
47. Pockros PJ, Nelson D, Godofsky E et al. R1626 plus PEG-interferon alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology 48, 385-397 (2008).
48. Stuyver LJ, McBrayer TR, Tharnish PM et al. Inhibition of hepatitis C replicon RNA synthesis by b-d-2′-deoxy-2′-fluoro-2′-C- methylcytidine: A specific inhibitor of hepatitis C virus replication. Antivir. Chem. Chemother. 17, 79-87 (2006)
49. Murakami E, Bao H, Ramesh M et al. Mechanism of activation of b-d-2′-deoxy-2′-fluoro-2′-C-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase. Antimicrob. Agents Chemother. 51, 503-509 (2007) (Pubitemid 46185267)
50. Ma H, Jiang WR, Robledo N et al. Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor b-d-2′-deoxy- 2′-fluoro-2′-C-methylcytidine (PSI6130) and identification of novel active 5′-Triphosphate species. J. Biol. Chem. 282, 29812-29820 (2007). (Pubitemid 350035263)
51. McHutchison JG, Reddy R, Rodriguez-Torres M et al. Potent antiviral activity of the nucleoside HCV inhibitor, R7128, in prior IFN nonresponders. Presented at: Frontiers in Drug Development in Viral Hepatitis (HEP-DART). Lahaina, Hawaii, USA, 9-13 December 2007.
52. Hecker SJ, Erion MD. Prodrugs of phosohonates and phosphates. J. Med. Chem. 51, 2328-2345 (2008)
53. Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues: Mechanisms of drug resistance and reversal strategies. Nat. Leukemia 15, 875-890 (2001) (Pubitemid 32529886)
54. Mackman RL, Cihlar T. Prodrug strategies in the design of nucleoside and nucleotide antiviral therapeutics. Annu. Rep. Med. Chem. 39, 305-321 (2004).
55. Ariza ME. Current prodrug strategies for the delivery of nucleotides into cells. Drug Des. Rev. Online 2, 373-387 (2005). (Pubitemid 41195662)
56. Mehellou Y, Balzarini J, McGuigan C. Aryloxyphosphoramidates triesters: A technology for delivering monophosphorylated nucleosides and sugars into cells. ChemMedChem 4, 1779-1791 (2009).
57. Zemlicka J. Lipophilic phosphoramidates as antiviral pronucleotides. Biochim. Biophys. Acta 1587, 276-286 (2002). (Pubitemid 34655795)
58. Poijarvi-Virta P. Prodrug approaches of nucleotides and oligonucleotides. Curr. Med. Chem. 13, 3441-3465 (2006). (Pubitemid 44873755)
59. McGuigan C, Pathirana RN, Mahmood N, Devine GK, Hay AJ. Aryl phosphate derivatives of AZT retain activity against HIV1 in cell lines, which are resistant to the action of AZT. Antivir. Res. 17, 311-321 (1992).
60. Devine KG, McGuigan C, O'Connor TJ, Nicholls SR, Kinchington D. Novel phosphate derivatives of zidovudine as anti-HIV compounds. AIDS 4, 371-372 (1990).
61. McGuigan C, Devine KG, O'Connor TJ, Galpin SA, Jeffries DJ, Kinchington D. Synthesis and evaluation of some novel phosphoramidate derivatives of 3′-azido-3′-deoxythymidine (AZT) as anti-HIV compounds. Antivir. Chem. Chemother. 1, 107-113 (1990).
62. McGuigan C, Devine K, O'Connor TJ, Kinchington D. Synthesis and anti-HIV activity of some haloalkyl phosphoramidate derivatives of 3′-azido- 3′-deosythymidine (AZT): Potent activity of the trichloroethyl methoxyalaninyl compound. Antiviral Res. 15, 255-263 (1991).
63. Balzarini J, Kruining J, Wedgwood O et al. Conversion of 2′,3′-dideoxyadenosine (ddA) and 2′,3′-didehydro- 2′,3′-dideoxyadenosine (d4A) to their corresponding aryloxyphosphoramidate derivatives markedly potentiates their activity against human immunodeficiency virus and hepatitis B virus. FEBS Lett. 410, 324-328 (1997). (Pubitemid 27304089)
64. Perrone P, Luoni GM, Kelleher MR et al. Application of the phosphoramidate protide approach to 4'-azidouridine confers sub-micromolar potency versus hepatitis C virus on an inactive nucleoside. J. Med. Chem. 50, 1840-1849 (2007). (Pubitemid 46626594)
65. Perrone P, Daverio F, Valente R et al. First example of phosphoramidate approach applied to a 4'-substituted purine nucleoside (4'-azidoadenosine): Conversion of an inactive nucleoside to a submicromolar compound versus hepatitis C virus. J. Med. Chem. 50, 5463-5470 (2007). (Pubitemid 350057856)
66. McGuigan C, Cahard D, Sheeka HM, De Clercq E, Balzarini J. Aryl phosphoramidate derivatives of d4T have improved anti-HIV efficacy in tissue culture and may act by the generation of novel intracellular metabolite. J. Med. Chem. 39, 1748-1753 (1996). (Pubitemid 26124246)
67. Balzarini J, Karlsson A, Aquaro S et al. Mechanism of anti-HIV action of masked alaninyl D4TMP derivatives. Proc. Natl Acad. Sci. USA 93, 7295-7299 (1996). (Pubitemid 26243543)
68. Balllatore C, McGuigan C, De Clercq E, Balzarini J. Synthesis and evaluation of novel amidate prodrugs of PMEA and PMPA. Bioorg. Med. Chem. Lett. 11, 1053-1056 (2001). (Pubitemid 32319979)
69. McGuigan C, Harris SH, Daluge SM et al. Application of phosphoramidate pronucleotide technology to abacavir leads to a significant enhancement of antiviral potency. J. Med. Chem. 48, 3504-3515 (2005). (Pubitemid 40664102)
70. McGuigan C, Hassan-Abdallah A, Srinivasan S et al. Application of phosphoramidate ProTide technology significantly improves antiviral potency of carbocyclic adenosine derivatives. J. Med. Chem. 49, 7215-7226 (2006). (Pubitemid 44886007)
71. McGuigan C, Serpi M, Bibbo R et al. Phosphate prodrugs derived from N-acetylglucosamine have enhanced chondroprotective activity in explant cultures and represent a new lead in antiosteoarthriritis drug discover. J. Med. Chem. 51, 5807-5812 (2008).
72. McGuigan C, Tsang HW, Sutton PW, De Clercq E, Balzarini J. Synthesis and anti-HIV activity of some novel chain-extended phosphoramidate derivatives of d4T (stavudine): Esterase hydrolysis as a rapid predictive test for antiviral potency. Antiviral Chem. Chemother. 9, 109-115 (1998). (Pubitemid 28160956)
73. McGuigan C, Sutton PW, Cahard D et al. Synthesis, anti-human immunodeficiency virus activity and esterase lability of some novel carboxylic ester-modified phosphoramidate derivatives of stavudine (d4T). Antiviral Chem. Chemother. 9, 473-479 (1998). (Pubitemid 28556662)
74. Abraham TW, Kalman TI, McIntee EJ, Wagner CR. Synthesis and biological activity of aromatic amino acid phosphoramidates of 5′-fluoro-2′- deoxyuridine and 1-b-arabinofuranosylcytosine: Evidence of phosphoramidase activity. J. Med. Chem. 39, 4569-4575 (1996). (Pubitemid 26382841)
75. Kim J, Chou TF, Griegraber GW, Wagner CR. Direct measurement of nucleoside monophosphate delivery from a phosphoramidate pronucleotide by stable isotope labeling and LC-ESI MS/MS. Mol. Pharm. 1, 102-111 (2004).
76. Iyer VV, Griesgaber GW, Radmer MR, McIntee EJ, Wagner CR. Synthesis, in vitro anti-breast cancer activity, and intracellular decomposition of amino acid methyl ester alkyl amide phosphoramidate monoesters of 3′-azido-3′- deoxythymidine (AZT). J. Med. Chem. 43, 2266-2274 (2000). (Pubitemid 30354551)
77. Gosselin G, Girardet JL, Periguad C et al. New insights regarding the potential of the pronucleotide approach in antiviral chemotherapy. Acta Biochim. Polym. 43, 195-208 (1996). (Pubitemid 126417422)
78. Lefebvre I, Perigaud C, Pompon A et al. Mononucleoside phosphotriester derivatives with S-acyl-2-Thioethyl Bioreversible phosphate-protecting groups: Intracellular delivery of 3′-azido-2′,3′-dideoxythymidine 5′-monophosphate. J. Med. Chem. 38, 3941-3950 (1995).
79. Periguad C, Gosselin G, Lefebvre I et al. Rational design for cytosolic delivery of nucleoside monophosphates: SATE and DTE as enzyme labile transient phosphate protecting groups. Bioorg. Med. Chem. Lett. 3, 2521-2526 (1993). (Pubitemid 24040964)
80. Valette G, Pompon A, Girardet JL et al. Decomposition pathways and in vitro HIV inhibitory effects of isoddA pronucleotides: Toward a rational approach for intracellular delivery of nucleoside 5′-monophosphates. J. Med. Chem. 39, 1981-1990 (1996).
81. Prhavc M, Dyatkina N, Keicher J et al. Synthesis and biological activity of 7-deaza-7-ethynyl-2′-deoxy-2′-C-methyladenosine and its 2′-C-Methyl-ribo analogue. Nucleic Acids Symp. Ser. 52, 643-644 (2008).
82. Bezaria S, Bardiot D, Bouisset T et al. 2′-C-Methyl branched pyrimidine ribonucleoside analogues: Potent inhibitors of RNA virus replication. Antivir. Chem. Chemother. 18, 225-242 (2007). (Pubitemid 47492965)
83. Gunic E, Girardet JL, Ramasamy K et al. Cyclic monophosphate prodrugs of base-modified 2′-C-methyl ribonucleosides as potent inhibitors of hepatitis C virus RNA replication. Bioorg. Med. Chem. Lett. 17, 2452-2455 (2007). (Pubitemid 46507791)
84. Zhou XJ, Pietropaolo K, Chen J et al. Safety and pharmacokinetics of IDX184, a liver-Targeted nucleoside polymerase inhibitor of hepatitis C virus, in healthy subjects. Antimicrob. Chem. Chemother. 55, 76-81 (2011).
85. LePage GA, Hersh EM. Cyclic nucleotide analogs as carcinostatit agents. Biochem. Biophys. Res. Commun. 46, 1918 (1972).
86. Gohil RN, Gillen RG, Nagyvary J. Synthesis and properties of some cyclic AMP alkyl phosphotriestres. Nucleic Acids Res. 12, 1691-1702 (1974).
87. Meyer RB, Stone TE. 2′-O-Acyl-6-Thioinosine cyclic 3′,5′-phosphates as prodrugs of thioinocinic acid. J. Med. Chem. 22, 811-815 (1997).
88. Engels J, Schlaeger EJ. Synthesis, structure, and reactivity of adenosine cyclic 3′,5′-phoaphate benzyl triesters. J. Med. Chem. 20, 907-911 (1977). (Pubitemid 8108901)
89. Reddy PG, Bao D, Chang W et al. 2′-deoxy-2′-a-fluoro- 2′-b-C-methyl 3′,5′-cyclic phosphate nucleotide prodrug analogs as inhibitors of HCV NS5B polymerase: Discovery of PSI352938. Bioorg. Med. Chem. Lett. 24, 7376-7380 (2010).
90. Meppen M, Pacini B, Bazzo R et al. Cyclic phosphoramidates as prodrugs of 2′-C-methycytidine. Eur. J. Med. Chem. 44, 3765-3770 (2009).
91. Erion MD, Reddy RK, Boyer SH et al. Design, synthesis and characterization of a series of cytochrome P450 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver. J. Am. Chem. Soc. 126, 5154-5163 (2004). (Pubitemid 38509471)
92. Erion MD, van Poelje PD, Mackenna DA et al. Liver-Targeted drug delivery using HepDirect prodrugs. J. Pharmacol. Exp. Ther. 312, 554-560 (2005). (Pubitemid 40189552)
93. Sorbera LA, Serradell N, Bolos J. Pradefovir mesilate treatment for hepatitis B. Drugs Future 32, 137-143 (2007).
94. Gardelli C, Attenni B, Donghi M et al. Phosphoramidate prodrugs of 2′-C-methylcytidine for therapy of hepatitis C virus infection. J. Med. Chem. 52, 5394-5407 (2009).
95. Carroll SS, Koeplinger K, Vavrek M et al. Antiviral efficacy upon administration of HepDirect prodrug of 2′-C-methylcytidine to hepatitis C virus-infected chimpanzees. Antimicrob. Agents Chemother. 55, 3854-3860 (2011).
96. Murakami E, Niu C, Bao H et al. The mechanism of action of beta-d-2′-deoxy-2′-fluoro-2′-C-methylcytidine involves a second metabolic pathway leading to beta-d-2′-deoxy-2′-fluoro- 2′-C-methyluridine 5′-Triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob. Agents Chemother. 52, 458-564 (2008).
97. Sofia MJ, Bao D, Chang W et al. Discovery of b-d-2′-deoxy-2′- fluoro-2′-C-methyluridine nucleotide prodrug (PSI7977) for the treatment of hepatitis C virus. J. Med. Chem. 53, 7202-7218 (2010).
98. Pharmasset reports positive preliminary antiviral data with Psi-7851 for the treatment of hepatitis C. Pharmasset 31 July 2009.
99. Murakami E, Tolstykh T, Bao H et al. Mechanism of activation of PSI7851 and its diasteroisomer PSI7977. J. Biol. Chem. 285, 34337-343347 (2010).
100. Lawitz E, Lalezari J, Rodriguez-Torres M et al. High rapid virological response (RVR) with PSI7977 daily dosing plus PEG-IFN/RBV in a 28-day Phase 2a trial. Presented at: 61st Annual Meeting of the American Association of the Study of Liver Diseases. Boston, MA, USA, 29 October-2 November 2010.
101. Lawitz E, Rodriguez-Torres M, Denning J et al. Once daily dual nucleotide combination of PSI938 and PSI7977 provides 94% HCV RNA
102. McGuigan C, Kelleher MR, Perrone P et al. The application of phosphoramidate ProTide technology to the potent anti-HCV compound 4'-azidocytidine (R1479). Bioorg. Med. Chem. Lett. 19, 4250-4254 (2009)
103. Perrone P, Luoni GM, Keheller MR et al. Application of the phosphoramidate ProTide approach to 4'-azidouridine confers sub-micromolar potency versus hepatitis C virus on an inactive nucleoside. J. Med. Chem. 50, 1840-1849 (2007) (Pubitemid 46626594)
104. Carroll SS, Tomassini JE, Bosserman M et al. Inhibition of hepatitis C virus RNA replication by 2′-modified nucleoside analogs. J. Biol. Chem. 278, 11979-11984 (2003). (Pubitemid 36800172)
105. McGuigan C, Perrone P, Madela K et al. The phosphoramidate ProTide approach greatly enhances the activity of b-2′-C-methylguanosine agains hepatitis C virus. Bioorg. Med. Chem. Lett. 19, 4316-4320 (2009).
106. Hecker SJ, Reddy KR, van Poelje PD et al. Liver-Targeted prodrugs of 2′-C-methyladenosine for therapy of hepatitis C virus infection. J. Med. Chem. 50, 3891-3896 (2007). (Pubitemid 47292052)
107. Carroll SS, Ludmerer S, Handt L et al. Robust antiviral efficacy upon administration of nucleoside analog to hepatitis C virus-infected chimpanzees. Antimicrob. Agents Chemother. 53, 926-934 (2009).
108. Cretton-Scott E, Periguad C, Peyrottes S et al. In vitro antiviral activity and pharmacology of IDX184, a novel and potent inhibitor of HCV replication. J. Hepatol. 18(Suppl. 2), S220 (2008).
109. Lallos L, LaColla M, Serra I et al. Combination of IDX184, a nucleotide prodrug polymerase inhibitor with other classes of HCV inhibitors is additive to synergistic in the HCV replicon in vitro. Presented at: 60th Annual Meeting of the American Assosiaction for the Study of Liver Diseases. Boston, MA, USA, 30 October-3 November 2009.
110. Standring D, Lanford R, Li B et al. Antiviral activity of the liver targeted nucleoside HCV polymerase inhibitor IDX184 correlates with trough serum levels of the nucleoside metabolite of HCV-infected chimpanzees. Presented at: 44th Annual Meeting of the European Association for the Study of the Liver, EASL. Copenhagen, Denmark, 22-26 April 2009.
111. Lalezari J, Asmuth D, Casiro A et al. Antiviral activity, safety and pharmacokinetics of IDX184, a liver-Targeted nucleotide HCV polymerase inhibitor, in patients with chronic hepatitis C. Presented at: 60th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA, USA, 30 October-3 November 2009.
112. Lalezari J, O'Riordan W, Poordad F et al. A Phase IIa studyof IDX184 in combination with PEGylated interferon (PEG-IFN) and ribavirin (RBV) in treatment-naïve HCV genotype 1-infected subjects. Presented at: 61st Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA, USA, 29 October-2 November 2010.
113. McGuigan C, Gilles A, Madela K et al. Phosphoramidate ProTides of 2′-C-Methylguanosine as highly potent inhibitors of hepatitis C virus. Study of their in vitro and in vivo properties. J. Med. Chem. 53, 4949-4957 (2010)
114. McGuigan C, Madela K, Aljarah M et al. Design, synthesis and evaluation of a novel double prodrug: INX08189. A new clinical candidate for hepatitis C virus. Bioorg. Med. Chem. Lett. 20, 4850-4854 (2010)
115. McGuigan C, Madela K, Aljarah M et al. Dual pro-drugs of 2′-C-methyl guanosine monophosphate as potent and selective inhibitors of hepatitis C virus. Bioorg. Med. Chem. Lett. 21, 6007-6012 (2011).
116. Vernachio JH, Blaiman B, Bryant KD et al. INX08189, a phosphoramidate prodrug of 6-O-methyl-2′-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties. Antimicrob. Agents Chemother. 55, 1843-1851 (2011).
117. Hall A, Chamberlain S, Ganguly B et al. Metabolite Characterization of INX189, a potent HCV inhibitor, in fresh human primary hepatocytes and human liver cell lines. Presented at: 61st Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA, USA, 29 October-2 November 2010.
118. Barry A, Patti J, Matson M et al. A study of the safety and pharmacokinetics of single ascending oral dose of INX08189, a nucleotide polymerase inhibitor, in healthy subjects. Presented at: 46th Annual Meeting of the European Association for the Study of the Liver, EASL. Berlin, Germany, 30 March-3 April 2011.
119. Chang W, Bao D, Chun BK et al. Discovery of PSI353661, a novel purine nucleotide prodrug for the treatment of HCV infection. ACS Med. Chem. Lett. 2, 130-135 (2010)
120. Reddy PG, Bao D, Chang W et al. 2′-Deoxy-2′-a-fluor-2′- b-C-methyl 3′,5′-cyclic phosphate nucleotide prodrug analogs as inhibitors of HCV NS5B polymerase: Discovery of PSI352938. Bioorg. Med. Chem. Lett. 20, 7376-7380 (2010)
121. Symonds WT, Denning JM, Albanis E et al. Pharmacokinetics, safety and tolerability of PSI352938, a novel nucleotide polymerase inhibitor for HCV, following single ascending oral doses in healthy subjects. Presented at: 61st Annual Meeting of the American Assosiaction for the Study of Liver Diseases. Boston, MA, USA, 29 October-2 November 2010.
122. Furman PA, Murakami E, Niu C. Activity and the metabolic activation patway of the potent and selective hepatitis C virus pronucleotide inhibitor PSI353661. Antivir Res. 91, 120-132 (2011)
123. Gunic E, Chow S, Rong F et al. 6-Hydrazinopurine 2′-methyl ribonucleosides and their 5′-monophosphate prodrugs as potent hepatitis C virus inhibitors. Bioorg. Med. Chem. Lett. 17, 2456-2458 (2007). (Pubitemid 46507790)
124. Zhou Y, Muh U, Hanzelka BL et al. Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: Sensitivity to telaprevir (VX0950) and interferon alpha. J. Biol. Chem. 282, 22619-22628 (2007). (Pubitemid 47267330)
125. Le Pogam S, Seshaadri A, Kosaka A et al. Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients. J. Antimicrob. Ther. 61, 1205-1216 (2008). (Pubitemid 351753583)
126. Le Pogam S, Seshaadri A, Kang H et al. Low levels of resistance, low viral fitness and absence of resistant mutations in baseline quasispecies may contribute to high barrier to R1626 resistance in vivo. J. Hepatol. 48(Suppl. 2), S10 (2008).
127. McCown MF, Rajyaguru S, Le Pogam et al. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob. Agents Chemother. 52, 1604-1612 (2008). (Pubitemid 351614649)
128. Ali S, Leveque V, Le Pogam S et al. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI6130 lack cross-resistance with R1479. Antimicrob. Agents Chemother. 52, 4356-4369 (2008).
129. Cheng G, Fenzux M, Mabery E et al. Nucleotide inhibitor resistance selections using GT2A infectious virus: PSI7851 and GS-6620 select for novel resistance pathway including substitutions of M289V/L followed by S282T. Presented at: 46th Annual Meeting of the European Association for the Study of the Liver, EASL. Berlin, Germany, March 30-3 April 2011.
130. Lam AM, Espiritu C, Micolochick Steuer H et al. Novel 2′-F-2′-C-methylpurine nucleotide analogs are active inhibitors of HCV replication and lack cross-resistance with other nucleos(t)ide analogs. Presented at: 61st Annual Meeting of the American Assosiaction for the Study of Liver Diseases. Boston, MA, USA, 29 October-2 November 2010.
131. Traut TW. Physiological concentrations of purines and pyrimidines. Mol. Cell. Biochem. 140, 1-22 (1994). (Pubitemid 24379884)